Human Investing’s ICL Group ICL Stock Holding History

Human Investing’s Portfolio ICL Stock Details ICL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-105	Closed	-$521	–	123
2024 Q4	$521	Buy	+105	New	+$470	﹤0.01%	310

Other funds holding ICL

Meitav Investment House Bene-Beraq, Israel $14.9B AUM 46.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

Y.D. More Investments Ramat Gan, Israel $3.21B AUM 117.29% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

KHLMVGHM

Kranot Hishtalmut Le Morim Ve Gananot Havera Menahelet Tel Aviv, Israel $2.44B AUM 24.95% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Human Investing's ICL Position: Q1 2025 in Review

Human Investing sold out of ICL Group (ICL) in Q1 2025, closing a stake of 105 shares — an estimated $521 sold.

Human Investing first reported a position in ICL in Q4 2024 and held it in 1 quarter. The position peaked at $521 in Q4 2024. 205 funds tracked by Wall St. Rank hold ICL as of Q1 2025.

Human Investing reported no remaining ICL Group position as of Q1 2025 after selling out during the quarter.
Human Investing sold 105 ICL Group shares in Q1 2025, an estimated $521.
Human Investing first reported a position in ICL Group in Q4 2024 and held it in 1 quarter.
Human Investing's ICL Group position peaked at $521 in Q4 2024.
205 funds tracked by Wall St. Rank held ICL Group as of Q1 2025.

Based on Human Investing's 13F filing for Q1 2025, filed 15 May 2025.